NASDAQ, CTIC - Cti Biopharm Corp.
We develop, acquire and commercialize novel treatments for cancer. Our goal is
to build a leading biopharmaceutical company with a diversified portfolio of
proprietary oncology drugs. Our research, development, acquisition and
in-licensing activities concentrate on identifying and developing new, less
toxic and more effective ways to treat cancer.
On December 21, 2007, we completed our acquisition of the U.S. development,
sales and marketing rights to the radiopharmaceutical product Zevalin?
(Ibritumomab Tiuxetan), or Zevalin, from Biogen Idec Inc., or Biogen, pursuant
to an Asset Purchase Agreement. Zevalin was the first radioimmunotherapy
approved by the U.S. Food and Drug Administration, or FDA. It was approved in
2002 to treat patients with relapsed or refractory low-grade, follicular, or
B-cell non-Hodgkin?s lymphoma, or NHL. The assets acquired included the Zevalin
FDA registration, FDA dossier, U.S. ...
Read SEC Filing on NASDAQ.com »